# Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

> **NCT01788280** · PHASE2 · WITHDRAWN · sponsor: **University of Utah**

## Conditions studied

- Glioblastoma Multiforme (GBM)

## Interventions

- **DRUG:** Fluciclitite , PET imaging, and Bevacizumab

## Key facts

- **NCT ID:** NCT01788280
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to get materials from GE, study not proceeding and never opened to accrual
- **Last updated:** 2018-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788280, "Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01788280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*